

# Pink1 is cleaved on healthy mitochondria

Chauss, D., Gillespie, ME., Kantorow, M., Varusai, TM.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

17/05/2024

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

## Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

**Pink1 is cleaved on healthy mitochondria** [↗](#)

**Stable identifier:** R-HSA-5205681

**Type:** transition

**Compartments:** mitochondrial intermembrane space



Full-length PINK1 (63 kDa), which is in the inner mitochondrial space, is proteolytically cleaved into a 52-kDa cytosolic fragment (111 - 581) that is released back into the cytoplasm by an unknown mechanism and degraded by the proteasome. Cleavage of PINK1 into an unstable cytosolic form maintains low levels of PINK1 on healthy mitochondria in order to suppress the PINK1/Parkin pathway in the absence of mitochondrial damage. At present, not all of the proteases mediating the cleavage of PINK1 in mammalian cells have been identified.

**Literature references**

Tanaka, A., Jin, SM., Cookson, MR., Narendra, DP., Suen, DF., Shen, J. et al. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol.*, 8, e1000298. [↗](#)

Kane, LA., Jin, SM., Wang, C., Narendra, DP., Lazarou, M., Youle, RJ. (2010). Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J. Cell Biol.*, 191, 933-42. [↗](#)

Narendra, DP., Youle, RJ. (2011). Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. *Antioxid. Redox Signal.*, 14, 1929-38. [↗](#)

**Editions**

2013-11-21	Authored, Edited	Gillespie, ME.
2015-09-01	Reviewed	Kantorow, M., Chauss, D.
2019-03-05	Revised	Varusai, TM.